
## Liam Morgan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6018771/publications.pdf Version: 2024-02-01



Ι ΙΑΜ ΜΟΡΟΑΝ

#	Article	IF	CITATIONS
1	In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing. Scientific Reports, 2017, 7, 6715.	1.6	6
2	Potential roles of suppressor of cytokine signaling in wound healing. Regenerative Medicine, 2016, 11, 193-209.	0.8	28
3	Mimicking the tumour microenvironment: three different coâ€culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. British Journal of Haematology, 2012, 158, 589-599.	1.2	45
4	Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Cell Proliferation, 2011, 44, 380-390.	2.4	26
5	The influence of leptin on trabecular architecture and marrow adiposity in GH-deficient rats. Journal of Endocrinology, 2011, 208, 69-79.	1.2	9
6	Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica, 2010, 95, 514-517.	1.7	10
7	Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically Cancer Biology and Therapy, 2009, 8, 1550-1558.	1.5	63
8	Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment, 2009, 115, 57-67.	1.1	66
9	Adverse Features of Acquired Antihormone Resistance and Their Targeting. , 2009, , 139-160.		1
10	Src as a Therapeutic Target in Breast Cancer. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 273-278.	0.6	17
11	Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clinical and Experimental Metastasis, 2007, 24, 157-167.	1.7	63
12	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Research and Treatment, 2006, 97, 263-274.	1.1	312
13	Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. International Journal of Cancer, 2006, 118, 290-301.	2.3	245
14	Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer, 2006, 13, S53-S59.	1.6	55
15	Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (Iressa', ZD1839). Clinical and Experimental Metastasis, 2004, 21, 201-212.	1.7	102